

1 **Creation of a Shortened Version of the of the Sleep**

2 **Disorders Questionnaire (SDQ)**

3

4 **Short Title: Short version of SDQ**

5

6

7 Kathleen Biard^{1¶}, Joseph De Koninck^{1¶2}, Alan B. Douglass^{2¶3*}

8

9

10 ¹ School of Psychology, Faculty of Social Sciences, University of Ottawa, Ottawa, Ontario,
11 Canada

12

13 ² University of Ottawa Institute of Mental Health Research at the Royal Ottawa Mental Health
14 Center, Ottawa, Ontario, Canada

15

16 ³ Psychiatry Department, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

17

18

19

20

21 *Corresponding author (ORCID ID 0001-6837-9799)

22

23 Email: alan.douglass@theroyal.ca (ABD)

24

25 ¶ These authors contributed equally to this work

26

27

28

29

30

31 **Funding:**

32 A Canada Graduate Scholarship (CGS) from the Natural Sciences and Engineering Research
33 Council (NSERC) supported the PhD studies of Dr. Biard and her analysis of the data.

34

35 **Competing Interests:**

36 Drs. Biard and De Koninck declare no competing interests

37 .

38 Dr. Douglass claims copyright of the resulting SDQ-2 questionnaire and may profit from its
39 future commercialization. He is also a paid consultant to the Ottawa Police Association, which
40 is sponsoring a validation study of the SDQ-2.

41

42

43

44

45

46

47

48

49 **Abstract:**

50

51 The 176-item Sleep Disorders Questionnaire (SDQ) was initially developed using canonical
52 discriminant function analysis on 4 groups of sleep disorder patients, but it was never studied by
53 factor analysis in its entirety. Several authors have criticized 2 of its subscales as being
54 confounded with each other, and its narcolepsy scale as substantially over-diagnosing
55 narcolepsy. This study describes its first exploratory factor analysis (EFA), the intent of which
56 was to reassess item membership on the 4 existing subscales and to derive new scales to improve
57 differential diagnosis between patient groups. It was also hoped that EFA could reduce the total
58 number of questions, to increase speed of completion. The EFA was performed on the
59 anonymized SDQ results from a retrospective review of the charts of 2131 persons from 7 sleep
60 disorders clinics and research centers. Factors were assessed via scree plots and eigenvalues.
61 The EFA identified four main factors: insomnia, daytime sleepiness, substance use, and sleep-
62 disordered breathing. The insomnia factor had 3 subfactors: psychological symptoms of
63 insomnia, subjective description of insomnia, and insomnia due to periodic limb movements.
64 The sleepiness factor had two subfactors: daytime sleepiness and neurological symptoms of
65 narcolepsy. The novel substance use factor was homogeneous, as was the sleep-disordered
66 breathing factor. Importantly, the EFA reassigned items from the original SDQ's NAR, PSY,
67 and PLM subscales to five of the new subscales. The Sleep Apnea (SA) subscale emerged
68 mostly unchanged. The 7 resulting factors comprised only 66 items of the original 176-item
69 SDQ. These results have allowed the creation of a new shorter questionnaire, to be called the
70 SDQ-2. External validation of the SDQ-2 is currently underway. It will likely prove to be a

71 superior differential diagnostic instrument for sleep disorders clinics, compared to the original
72 SDQ.

73 **List of Abbreviations**

74 Berlin Questionnaire: screening questionnaire for sleep apnea

75 BMI: Body Mass Index (kg/m²)

76 EFA: exploratory factor analysis

77 ESS: Epworth Sleepiness Scale

78 GAD-7: Generalized Anxiety Disorder, 7-item scale

79 MIES: Moral Injury Events Scale

80 NAR, PSY, PLM, SA: subscales of the original SDQ

81 OSA: obstructive sleep apnea

82 PCL-5: PTSD Checklist for DSM-5

83 PHQ-9: Patient Health Questionnaire (depression)

84 PLM: periodic limb movements

85 PSQI: Pittsburgh Sleep Quality Index

86 RLS: Restless Legs Syndrome

87 ROC: receiver operating characteristics (analysis)

88 SDB: sleep disordered breathing

89 SDQ: the original Sleep Disorders Questionnaire, 1994

90 SDQ-2: second edition of the SDQ, derived in the present paper

91 SQAW: Stanford University's Sleep Questionnaire and Assessment of Wakefulness

92 STOP-Bang: screening questionnaire for sleep apnea

- 93 TIA: transient ischemic attack
- 94 CAGE: alcohol screening questionnaire
- 95 ISI: Insomnia Severity Index
- 96

98 **Introduction:**

99 The aim of the original Sleep Disorders Questionnaire (SDQ) was to provide a self-report
100 tool to assess the risk of having one of several sleep disorders. It was developed between 1983
101 and 1994 by Douglass and colleagues[1] at Stanford University from their existing Sleep
102 Questionnaire and Assessment of Wakefulness (SQAW)[2]. The latter had been difficult to use
103 clinically due to its great length, over 800 items, and its many different response sets. SDQ
104 retained only 175 of its items, which were then grouped, simplified, re-worded, and all changed
105 to 5-point Likert scales. Body mass index (BMI) was added as the 176th item, to be entered by a
106 clinician.

107 SDQ items were deemed to have adequate face validity when assessed by three Stanford
108 sleep specialists, and were validated against polysomnographic diagnoses in a canonical
109 discriminant function analysis of 519 patients[1]. This resulted in four subscales characteristic of
110 patients with common sleep disorders (subscale name in brackets): narcolepsy (NAR), sleep
111 apnea (SA), periodic limb movement disorder (PLM) and sleep disturbance due to psychiatric
112 illness (PSY). Receiver Operating Characteristics (ROC) analysis for each subscale
113 demonstrated adequate sensitivity, specificity, and positive / negative predictive values. Item
114 test-retest reliability of the SDQ items was assessed by Pearson correlation over an interval of 3
115 to 4 months in 130 patients and 71 normal controls[3]; the range of correlation was from $r =$
116 0.308 to 0.985, mean $r^2 = 0.636$.

117 With its focus on diagnosis, SDQ differed from scales like the Pittsburgh Sleep Quality
118 Index (PSQI)[4], which focus on subjective descriptions of sleep that correlate most strongly
119 with psychological mood and anxiety questionnaires. Another focus of SDQ has been the
120 identification of sleep disorders that are co-morbid with other medical and psychiatric diagnoses.

121 This was exemplified by a study[5] using SDQ and the NoSAS questionnaire to look for sleep
122 apnea in patients with diagnosed depression. Similarly, a controlled study[6] showed significant
123 elevations of the PSY and PLM scales in patients with COPD.

124 Using the German translation of the SDQ, a study[7] of 3521 patients undergoing
125 polysomnography showed significant sex differences by ANOVA within the 4 SDQ scales,
126 which the authors postulated might explain the under-recognition of sleep-disordered breathing
127 (SDB) in women.

128 A brief review of the literature regarding the 4 existing subscales of the SDQ and
129 problems with their usage is as follows:

130 **SDQ-PLM subscale:** A 2006 study of 4,901 Swiss pharmacy customers by
131 Schwegler[8] factor analyzed 45 items from the French and German translations of the SDQ.
132 Their goal was to confirm the uniqueness of the 4 original SDQ subscales and to use the Epworth
133 Sleepiness Scale[9] as an external validator. While their Cronbach's alpha coefficients for
134 subscale homogeneity were similar to those in the original SDQ paper, they found that 60% of
135 respondents scored above the originally-proposed pathological cut-off score of the PLM subscale
136 (which they called "RLS scale"). They also found that the SDQ-PSY subscale had Spearman
137 correlations of nearly 0.50 with both the PLM and NAR subscales, belying its intended purpose
138 of identifying sleep disturbance in patients with psychiatric illness. To date, few other papers
139 have reported use of the SDQ-PLM subscale. A validation by Valencia-Flores[10] found a
140 correlation (Spearman's rho = 0.59) between the SDQ-PLM subscale and the PLM index on
141 polysomnography in 14 patients with systemic lupus erythematosus. This subscale has also been
142 used to screen for causes of sleep problems in dementia patients[11]. Overall, SDQ's PLM

143 subscale appeared to be tapping into more general features of insomnia rather than those due
144 only to true RLS/PLMD.

145 **SDQ-NAR subscale:** This subscale was intended to be sensitive to the symptoms of
146 patients suffering narcolepsy-cataplexy (narcolepsy type 1), but it also proved to include items
147 that were endorsed by respondents who were sleepy due to other causes. Another surprise in the
148 Schwegler study[8] was that 10% of their respondents scored above the 90th percentile on the
149 NAR subscale. Since the population prevalence[12] of narcolepsy is less than 50/100,000, the
150 SDQ-NAR subscale obviously grossly over-diagnosed narcolepsy. These results suggested that
151 the NAR subscale might be reflecting non-narcoleptic sleepiness in the general population, in
152 addition to neurological symptoms of narcolepsy. Unexpectedly, Parkinson Disease patients also
153 scored significantly higher on the NAR subscale than controls[13], although this was attributed
154 to side-effects of their dopaminergic medications rather than to narcolepsy.

155 **SDQ-SA subscale:** Some papers refer to this as “SA-SDQ”, but the preferred
156 acronym is “SDQ-SA”. Its diagnostic intent was similar to that of other obstructive sleep apnea
157 (OSA) questionnaires in the literature, such as the Berlin[14], STOP-Bang[15], NoSAS[16], and
158 the OSA50[17]. In contrast to these, however, the SDQ-SA did not require any physical
159 measurements or interaction with a clinician. SA is the SDQ subscale most commonly reported
160 in the literature[18-21], likely due to its high sensitivity, specificity, PPV, and NPV when
161 compared[22] to other sleep apnea questionnaires. Recent meta-analyses and reviews[23-26]
162 have also supported the diagnostic usefulness of the SA subscale.

163 A much larger Swiss pharmacy study[27] of nearly 200,000 persons employed the SDQ-
164 SA (called “SAS” by the authors) along with the Epworth Sleepiness Scale (ESS) to predict

165 motor vehicle accidents due to sleepiness. They found that SDQ-SA subscale homogeneity by
166 Cronbach's alpha was again similar to the value in the original Douglass paper at $\rho = 0.74$.

167 Malow[28] found that SDQ-SA scores were significant predictors of ESS scores in 158
168 epilepsy patients, whereas anti-epileptic medication dose or seizure frequency were not.
169 Weatherwax[29] suggested that the original cutoff scores for diagnosing OSA in the general
170 population should be lowered for epilepsy patients. The SDQ-SA subscale has also been used to
171 identify OSA in patients with transient ischemic attacks (TIAs)[30-33] and in those with morbid
172 obesity[34].

173 **SDQ-PSY subscale:** Scores on this subscale are high in hospitalized patients with
174 major mood disorders or psychosis, likely due to the insomnia and sleep fragmentation often
175 reported by these patients. It was partially validated[35] by correlation with the Carroll
176 Depression Scale[36] in 44 patients diagnosed with Major Depressive Disorder ($r = 0.70$, $p <$
177 0.0001). It also showed significant negative correlation with sleep efficiency on the
178 polysomnograms of these same patients ($r = -0.30$, $p < 0.05$). Brower[37] used this subscale to
179 assess the subjective sleep complaints of 74 patients recovering from alcohol dependence in a
180 search for symptoms predictive of alcoholism relapse. Relapsers proved to have higher baseline
181 scores on the SDQ-PSY subscale than those who abstained over a follow-up period of 3 – 12
182 months. Some authors, including Brower, have however argued that the SDQ-PSY subscale is
183 actually an insomnia subscale, based on their own studies [38,39]. In support, Sweere[40]
184 performed a cluster analysis on a Dutch translation of 89 items from the SDQ and found a clear
185 insomnia subscale in addition to 2 others that closely resembled the SDQ's SA and NAR
186 subscales.

187 Taken together, the above findings suggest that the use of SDQ in non-clinical
188 populations sometimes substantially over-diagnoses sleep pathologies. They also imply that
189 some SDQ subscales are confounded with each other, possibly due to items concerning insomnia
190 appearing on more than one subscale. Some of these problems could also be due to the fact that
191 the original SDQ scales were derived not by factor analysis but rather by canonical discriminant
192 function analysis on responses from 4 polysomnographically-diagnosed groups of sleep disorder
193 patients.

194 Over the past 35 years, SDQ has been administered to tens of thousands of persons in
195 medical and surgical outpatient clinics, general hospital inpatients, psychiatric hospitals, sleep
196 disorders centers, and university psychology departments. It has been translated into French,
197 Dutch, German, Italian, Spanish, Greek, Arabic, and Turkish; therefore, there is a substantial
198 pool of data available for secondary analysis if the above problems could be resolved.

199 The rationale for the present study was to perform secondary analysis of new data to
200 reassess the factor structure of the 4 existing subscales via EFA. It was also hoped that new
201 subscales could be derived, such as a specific insomnia subscale. Finally, it was hoped to reduce
202 the total number of questions from 176 to a more manageable size for the SDQ-2 revision.

203

204 **Methods:**

205 In all, SDQ responses of 2185 adults (1543 males, 642 females) were obtained for
206 secondary analysis from a variety of hospitals and universities at which the SDQ had been
207 completed prior to a laboratory nocturnal polysomnogram. Responses were gathered over the
208 period 1986 – 2007, data collation was completed in 2008, and computer analysis took place
209 from 2008-2011. These data therefore represented a sample of convenience and not a population

210 sample planned in advance. Since most of these sites were either psychiatric facilities or general
211 sleep disorders centers, the focus of the SDQ is necessarily slanted towards symptoms
212 experienced by such patients rather than the general population. Polysomnographic data are not
213 reported here but will be reported in future papers on subscale validation.

214 Of the above total, 1356 participants were patients of Dr. Douglass at various hospitals,
215 meaning that he was aware of their identities. The IRB allowed SDQs on these charts to be
216 retrospectively reviewed with the proviso that their anonymity be ensured by assigning code
217 numbers as case identifiers, instead of patient names or hospital chart numbers, before being
218 included in the analysis. In the case of patients from other doctors or hospitals, code numbers
219 were used exclusively. The data from 54 cases (2.5% of total) were discarded because more than
220 20% of items were unanswered, leaving the data of 2131 persons (1497 males, 634 females) for
221 the EFA. This gave a patient-to-questionnaire-item ratio of 12:1, which is commonly regarded
222 as adequate for multivariate analysis. Any remaining missing values among the 176 items were
223 replaced by using a multiple imputation procedure (“PROC-MI”, SAS version 9.1, SAS Institute,
224 Cary, North Carolina), which operates via an iterative process. This version of SAS software
225 was also used to compute the EFAs (“PROC-FACTOR”) using a varimax factor rotation of both
226 orthogonal and oblique types. Eigenvalues and scree plots were used to determine the final
227 number of factors to be retained.

228 We then examined the items in each factor by condition index to determine if there was
229 significant collinearity; if so, all but one of the collinear variables was deleted. After the main
230 factors had been determined, a secondary factor analysis was run on some factors that proved to
231 be heterogeneous, in order to identify possible subfactors.

232 The original SDQ had 9 gender-specific items (4 for males, 5 for females). We dealt with
233 these by removing all of them from the main factor analysis. We then split the file by sex and
234 analyzed the responses of males and females separately, after removing items from the opposite
235 sex. This also allowed us to verify whether the factor structure was similar in men and women.
236 More detailed explanations of the statistical methods and results are shown in the Supporting
237 Information section.

238 Under an authorization dated 2008-04-11 by the *University of Ottawa Social Sciences*
239 *and Humanities Research Ethics Board* (File 02-08-16), secondary use of anonymized data from
240 the institutions listed in the attached “Thank-you Attestation” was approved. The project was
241 also approved in 2008 (File number 2008001) by the *Research Ethics Board of the Royal Ottawa*
242 *Hospital*.

243

244 **Results:**

245 Clinical and demographic details about the SDQ respondents are found in Table 1. Fifty-
246 four cases were deleted due to missing data, giving a case-wise missing rate of 2.5%. After
247 deletions, the remaining variable-wise average missing rate was 3.1%, all of which were replaced
248 by imputed values.

249

250 **Table 1: Characteristics of the respondents (n = 2185^c).**

251

DIAGNOSTIC GROUP	MALES			FEMALES		
	N	Mean Age	SD	N	Mean Age	SD
Psychiatric Patients ^a	574	45.18	13.41	296	41.85	12.67
General Practice Referrals ^b	899	45.23	13.77	338	44.78	13.79
Normal control subjects	70	38.70	12.71	8	38.61	12.73
SUBTOTALS	1543	44.92	13.59	642	43.35	13.27
Male + Female TOTAL				2185		

54 removed (missing data) 1497 2131 634

252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272

Table 1 Legend:

^a Hospital inpatients and outpatients with mood disorders, schizophrenia, anxiety disorders, PTSD, or alcoholism. They were usually studied clinically to rule-out a possible physical sleep disorder but some took part in research sleep studies (baseline nights). All patients were studied without CPAP or other physical treatment for sleep apnea.

^b Patients with a medical / surgical diagnosis who were referred by their general practitioner or specialist to rule out sleep apnea or physical causes of insomnia.

^c A total of 54 respondents (2.5% of total) were removed due to having $\geq 20\%$ missing items.

The EFA revealed four Main Factors when using a visually-determined scree cutoff, all of which had an eigenvalue > 5.0 (Fig. 1).

=====
****** insert Fig. 1 about here ******

Fig. 1 Legend:

Scree Plot of all factors extracted by the EFA. The first 4 factors all have eigenvalues greater than 5, and are referred to as Main Factors in the text.

=====
=====

273

274 The percentage of overall variance explained by these factors is shown in Table 2.

275 **Table 2: Percentage of overall variance explained by the 4 Main Factors.**

276

Factor ^a	Orthogonal Rotation	Oblique Rotation	
		Shared variance	Unique variance
1	12.76	15.43	8.92
2	8.89	11.53	6.69
3	6.68	8.67	5.91
4	6.57	6.46	6.43
TOTAL	34.90	42.09	27.95

277

278

279

280 **Table 2 Legend:**

281 ^a Factor numbers in the table refer to those in Figure 1.

282

283

284 Inter-correlations of the Main Factors' oblique rotations are shown in Table 3.

285

286

287

288 **Table 3: Inter-Correlations of the 4 Main Factors (Oblique rotation).**

289

	Factor1	Factor2	Factor3	Factor4
Factor1	1	0.264	0.189	-0.021
Factor2		1	0.097	0.069
Factor3			1	-0.091
Factor4				1

290

291

292 **Table 3 Legend:**

293 These intercorrelations demonstrate adequate independence of the Main Factors, considering that

294 Factors 1 and 2 have subfactors. This table was calculated on Factors from which collinear items

295 had been removed.

296

297

298 Secondary EFA of Main Factor 1 resulted in 3 subfactors with clinical relevance, while
299 the same process on Main Factor 2 resulted in 2 subfactors. Therefore, 7 useful factors were
300 extracted from the SDQ data. Scree plots of the secondary EFAs for Main Factors 1 to 4 are
301 described in Figs. S1 -- S4.

302 Item loadings on the Main Factors and their subfactors are shown in Tables 4 – 7. In
303 these tables, items that were also present on the four original SDQ subscales are identified with
304 different markers. Items selected for the final SDQ-2 subscales had to have item loadings of 0.4
305 or greater on the above factors.

306 Subscale homogeneity was calculated via Cronbach's alpha for each of the 7 subscales
307 and is shown below.

308 Collinearity diagnostics on all factors are shown in S1 Appendix, along with the names of
309 items that were removed to resolve the collinearity. The number of items removed from Main
310 Factors 1 – 4 by this process were 0, 2, 1, and 2, respectively.

311 In addition to the four Main Factors, another 15 factors resulted from the primary EFA,
312 numbered 5 – 19, all with eigenvalues ≥ 1 . The subject matter of these factors and their item
313 loadings are summarized in S1 Table. While they do not uniquely identify any clinical sleep
314 disorders, they may be of interest to some readers considering the large pool of respondents in
315 this study. Examples of their content include: psychosomatic causes of insomnia; seizures and
316 parasomnias; tonsil and adenoid problems; and sleepiness due to shift work.

317 Below is a detailed description of the 7 factors identified above and their homogeneity
318 (Cronbach's alphas). These factors are proposed to be the subscales of the new SDQ-2.

319

320 **Main Factor 1: Insomnia:**

321 **Subfactor 1A “InsPsy”:** Psychological features of insomnia ($\alpha = 0.919$)

322 **Subfactor 1B “InsSubj”:** Subjective description of insomnia severity ($\alpha = 0.831$)

323 **Subfactor 1C “InsPLM”:** Insomnia due to leg sensations ($\alpha = 0.823$)

324

325

326 Table 4 lists items that load on Main Factor 1 using an orthogonal rotation. Results for

327 the oblique rotation were similar. This factor incorporates 5 items from the original SDQ-PSY

328 subscale (marked with “Ψ”), as well as 5 from the original SDQ-PLM subscale (marked with

329 “L”). Also shown are 7 of the SDQ items from Brower’s 1998 insomnia subscale[37]. The

330 scree plot of the secondary factor analysis of Main Factor 1 (S1 Fig.) does not have a clear visual

331 cut-off but there are 3 factors having an eigenvalue ≥ 1 . When using an orthogonal rotation,

332 Subfactor 1A explained 6.1% of the overall dataset variance, subfactor 1B explained 5.6% and

333 subfactor 1C explained 2.8%. Subfactor 1A included psychological items such as “my sleep is

334 disturbed by worrying.” Subfactor 1B is a subjective description of insomnia severity, with items

335 such as “I get too little sleep at night.” The 4 items on Subfactor 1C describe limb movements

336 disturbing sleep.

337 =====

338

339

340 **Table 4: Item loadings on each subfactor of Main Factor 1 (orthogonal rotation).**

341

342

Item	1A	1B	1C	Source ^a	Brief Item Description
34	0.801	0.187	0.173	-	sleep disturbed by worrying
8	0.787	0.121	0.172	-	worry about things at bedtime
33	0.761	0.169	0.196	Ψ	sleep disturbed by sadness or depression
7	0.737	0.116	0.195	Ψ	feel sad and depressed at bedtime
32	0.711	0.268	0.196	-	sleep disturbed by racing thoughts
6	0.681	0.201	0.129	Ψ	thoughts race through my mind at bedtime
10	0.625	0.398	0.176	-	afraid of not being able to go to sleep
36	0.587	0.370	0.183	-	being unable to get back to sleep if should wake
130	0.566	0.226	0.060	-	mental stress, worry, or anxiety worsens sleep
13	0.537	0.487	0.125	-	not able to get to sleep once awake at night
3	0.517	0.510	0.144	Ψ*	have trouble getting to sleep at night
17	0.390	0.240	0.138	-	sleep is disturbed by noise
2	0.174	0.802	0.177	*	a poor night's sleep
87	0.169	0.761	0.182	*	problem with sleep
14	0.195	0.731	0.285	-	night sleep is restless and disturbed
1	0.209	0.714	0.097	*	too little sleep at night
44	0.121	0.707	0.180	*	feel that sleep is abnormal
4	0.132	0.685	0.185	L*	wake up often during the night
45	0.432	0.547	0.088	L*	respondent suspects they have insomnia
154	0.295	0.469	0.022	L	longest wake period at night
43	0.368	0.403	0.084	Ψ*	been unable to sleep at all for several days
114	0.308	0.367	0.147	-	prescription hypnotics [<i>kept due to face validity</i>]
153	-0.263	-0.552	-0.040	-	hours of sleep at night [<i>reverse coded on SDQ-2</i>]
31	0.124	0.209	0.837	L	sleep disturbed by "restless legs"
12	0.151	0.207	0.808	L	have "restless legs" when falling asleep
35	0.323	0.167	0.678	-	sleep disturbed by muscular tension
9	0.370	0.183	0.632	-	muscular tension at bedtime

343

344 **Legend for Table 4:**

345 Subfactor loadings are shown in order of decreasing magnitude. Loadings in gray highlight

346 indicate factor loadings of 0.4 or greater that were selected as SDQ-2 scale items.

347 **Item:** Numerical label of this item on the original SDQ.

348 **1A:** Subfactor related to psychological causes of insomnia.

349 **1B:** Subfactor related to a subjective description of insomnia severity.

350 **1C:** Subfactor related to insomnia attributed to leg sensations.

351 **^aSource:** Indicates item appeared on a subscale of the original SDQ, as follows:

352 **L:** SDQ-PLM subscale.

353 **Ψ:** SDQ-PSY subscale.

354 **“*”:** Brower’s insomnia subscale[37] that predicts alcoholism relapse.

355 **“-“:** Was not a member of an SDQ subscale.

356 =====

357

358 Items 17 (“sleep is disturbed by noise”) and 114 (“use prescription hypnotics to sleep”) only approached criterion on subfactors A and B (loadings of 0.39 and 0.37 respectively) but will be included in those subfactors due to face validity. Items 3, 13 and 45 co-load on both subfactors A and B. Item 13 (“I fear not being able to get back to sleep after waking”) will be associated with subfactor 1A while item 3 (“trouble getting to sleep at night”) and item 45 (“suspect that I have insomnia”) will be associated with subfactor 1B.

364

365 **Main Factor 2: Narcolepsy and Daytime Sleepiness**

366 **Subfactor 2A “EDS”:** Excessive Daytime Sleepiness ($\alpha = 0.827$)

367 **Subfactor 2B “NAR”:** Narcolepsy symptoms ($\alpha = 0.829$)

368

369 Table 5 lists items that have a loading of 0.4 or higher on either the orthogonal or oblique rotations on this factor. Main Factor 2 incorporates 13 of the 15 items from the original SDQ-NAR (narcolepsy) subscale, which are marked with “#”.

372

373

374

375 **Table 5: Item loadings on each subfactor of Main Factor 2 (orthogonal rotation).**
 376

Item	2A	2B	Source	Brief Item Description
55	0.834	0.149	#	very sleepy during the day, struggle to stay awake
41	0.714	0.101	-	sometimes very sleepy in the daytime, in cycles
58	0.700	0.201	#	trouble doing job because of sleepiness / fatigue
59	0.652	0.176	#	too sleepy to drive
56	0.599	0.144	#	fall asleep eating, on phone, in bus, TV, reading, etc.
42	0.582	0.272	#	have slept/been sleepy for several days at a time
158	0.518	0.136	-	number of daytime naps
157	0.467	0.215	-	car accidents due to sleepiness
91	0.429	0.100	-	sleeping more than previously
115	0.281	0.280	-	prescription drug to stay awake in day
161	-0.290	-0.042	-	refreshed for how long after day nap
39	0.415	0.743	#	Feel paralyzed after a nap
60	0.126	0.681	#	hallucinations before/after nap while awake
11	0.034	0.661	#	paralyzed when falling asleep
40	0.047	0.657	#	hallucinations after waking in the morning
67	0.243	0.617	#	sudden muscular weakness with strong emotions
61	0.228	0.595	-	vivid dreams during naps
66	0.193	0.585	#	“weak knees” when laughing
64	0.313	0.495	-	nonsense behaviour
63	0.330	0.446	#	driven car to wrong place, can’t remember how
57	0.316	0.357	#	bad grades in school because of sleepiness
156	0.255	0.260	-	work accidents due to sleepiness

377

378 **Legend for Table 5:**

379 **Item:** Numerical label of this item on the original SDQ;

380 **2A:** Subfactor related to excessive daytime sleepiness;

381 **2B:** Subfactor related to neurological symptoms of narcolepsy;

382 **Source:** This item appeared on a subscale of the original SDQ, as follows:

383 “#”: SDQ-NAR subscale

384 “-“: Was not a member of an SDQ subscale.

385

386 The scree plot (S2 Fig.) from the secondary factor analysis on Main Factor 2 showed a
 387 clear visual cut-off point after the second factor. Subfactor 2A explained 4.9% of the overall
 388 dataset variance and included items that describe subjective daytime sleepiness from any cause
 389 (“I am sometimes too sleepy to drive”). Subfactor 2B explained 4.6% of the overall variance and
 390 describes classical symptoms of narcolepsy (“I am paralyzed when falling asleep”).

391 No items co-loaded onto the two subfactors. SDQ items 115, 161, and 156 did not load
 392 significantly onto either subfactor, nor on the main factor and so will be omitted.

393

394 **Main Factor 3: Substances Affecting Sleep (“SUBST”), $\alpha = 0.685$**

395 This factor concerns persons who report substance use or abuse and its effect on sleep.

396 Table 6 lists the items that have a loading of 0.4 or higher on this factor, on either the orthogonal
 397 or oblique rotations. Factor 3 bears no relation to any subscale of the original SDQ.

398

399

400 **Table 6: Item loadings on each subfactor of Main Factor 3 (orthogonal rotation).**

401

Item	3A	3B	Source	Brief Item Description
105	0.773	0.063	-	use alcohol in order to get to sleep
111	0.698	0.059	-	used marijuana to help get to sleep
109	0.698	0.102	-	used "street drugs"
107	0.697	0.100	-	unaware of actions when drinking
110	0.637	0.044	-	used tobacco to help get to sleep
108	0.633	0.055	-	tobacco within 2 hours of bedtime
165	0.023	0.861	-	weight at age 20
172	0.071	0.831	-	height
Gender	-0.158	-0.821	-	1 = male, 2 = female

402

403 **Legend for Table 6:**

404 Main Factor 3 relates to subjective sleep difficulties related to substance use or abuse.

405 **Item:** Numerical label of this item on the original SDQ.

406 **3A, 3B:** Sub-factorizations of Main Factor 3. Items on 3B *were not kept* for SDQ-2

407 **Source:** None of these items appeared on any subscale of the original SDQ.

408 =====

409 We performed a secondary factor analysis on this third factor to determine if it was
410 homogenous. The scree plot (S3 Fig.) shows a clear visual cut-off after the second factor,
411 eigenvalue >1. Subfactor 3A explains 3.5% of the overall dataset variance while subfactor 3B
412 explains 2.1%. Subfactor 3A included all of this subfactor's items except 3 that are linked to
413 males: gender, item 172 (height), and item 165 (weight at age 20). It seems likely that the last
414 two items are included due to collinearity with the gender item and are not linked to substance
415 use, so they will not be considered legitimate items for this subfactor. Therefore, only gender
416 will be retained, and on a unitary factor 3.

417

418 **Main Factor 4: Sleep Disordered Breathing (“SDB”), $\alpha = 0.762$**

419 This factor incorporated 10 of the 12 items from the original SDQ-SA subscale (marked
420 with “@” in Table 7). This table also lists the items that have a loading of 0.4 or higher on this
421 factor, in either orthogonal or oblique rotations.

422

423

424 **Table 7: Item loadings on each subfactor of Main Factor 4 (orthogonal rotation).**

425

426

Item	4	4A	4B	Source	Brief Item Description
21	0.744	0.757	0.320	@	snore loudly and bother others
141	0.631	0.711	0.172	@	snoring / breathing problem worse on back
22	0.654	0.672	0.243	@	stop breathing in sleep
143	0.373	0.611	0.058	-	snoring / breathing worse with allergy / infection
23	0.479	0.572	0.111	@	awake suddenly gasping for breath
15	0.463	0.559	0.110	-	sleep disturbs bed partner's sleep
139	0.330	0.511	-0.054	-	nose blocking up when trying to sleep
142	0.409	0.486	0.136	@	snoring / breathing problem worse after alcohol
173	0.416	0.309	0.136	@	age
71	0.390	0.283	0.250	@	high blood pressure <i>[retained for face validity]</i>
163	0.722	0.213	0.918	@	current weight
165	0.504	0.018	0.794	-	what was your weight at age 20
172	0.636	0.245	0.751	@	how tall are you
144	0.440	0.405		-	completed menopause? 1=no . . . 5=agree strongly
“176”	0.636	0.245	0.641	@	available via “look-up matrix” using 163 & 172

427

428 **Legend for Table 7:**

429 **Item:** Numerical label of this item on the original SDQ;

430 **4:** Main Factor 4, prior to factoring into 4A and 4B. However, after consideration
431 of weight questions (see discussion in the text), Factor 4 was retained in its entirety

432 **4A:** Subfactor related to symptoms of sleep disordered breathing

433 **4B:** Subfactor related to weight, weight gain, and height

434 **Source:** If marked “@”, item was on the SA (sleep apnea) subscale of the original SDQ

435 If marked “-”, item did not appear on any subscale in the original SDQ.

436

437 We performed a secondary factor analysis on Factor 4 to determine if it was

438 homogenous. The scree plot (S4 Fig.) shows two factors with an eigenvalue > 1. Using an

439 orthogonal rotation, subfactor 4A explained 4.1% of the overall dataset variance while subfactor

440 4B explained 3.6% of the variance. Results for the oblique rotation were not much different.
441 Subfactor 4A contains items pertaining to breathing difficulties such as “I snore.” Subfactor 4B
442 contains items concerning gender and weight. Since 4B items also have face validity for an
443 apnea scale, Main Factor 4 will therefore be regarded as unitary. Item 18 (“I suffer from
444 heartburn and choking”) did not significantly load on either subfactor nor does it significantly
445 load on the main factor, so does not merit inclusion in SDQ-2.

446 It is worth noting that items “weight at age 20” and “weight 6 months ago” were
447 originally included in the SDQ in order to investigate the observation by some sleep medicine
448 professionals that apnea patients tend to gain weight over time, often rapidly. Therefore, two new
449 variables “weight gained in the past 6 months” and “weight gained since age 20” were calculated
450 from existing items. The former did not load significantly on any factor, but “weight gain since
451 age 20” loaded onto Factor 4 with weight 0.56. The latter has been drafted as a new item for
452 SDQ-2.

453 Item 144 (“I have gone through the menopause”) will be used only in the female version
454 of the SDQ-2’s SDB subscale, which will therefore be one item longer than the male version.
455 Item 172 (“How tall are you?”) has been retained on this subscale, since Item 176 (BMI) will not
456 be specifically asked about on the SDQ-2. Rather, a 5 x 5 cell look-up table (see S2 Table)
457 comprised of items 172 (height) and 163 (weight) will be supplied to users to allow them to
458 make an approximate calculation of BMI if this is desired.

459

460 **Factor Analyses by Gender**

461 Gender items were first removed from the dataset, after which it was split into male and
462 female datasets. Separate factor analyses performed on the latter produced similar factor

463 structures and item loadings. Interestingly, subfactors 2A and 2B (narcolepsy and daytime
464 sleepiness) came out as their own factors in both the male and female datasets, as opposed to
465 being subfactors of a Main Factor in the combined dataset. The other factors in the gender-based
466 analysis did not differ markedly from those in the combined data set.

467 When the gender-related items were put back into the split analyses, none of the four
468 items for men loaded significantly on any of the main factors. They did load onto their own
469 separate factor which could be considered a subscale of erectile dysfunction, but these items will
470 not be included as a separate subscale on the SDQ-2.

471

472 **DISCUSSION:**

473 This EFA of the original 176-item SDQ succeeded in its goals. It confirmed and resolved
474 problems with the 4 subscales of the original SDQ, notably their conflation of general daytime
475 sleepiness with neurological symptoms of narcolepsy, and a similar conflation of psychiatric
476 insomnia symptoms with those of simple insomnia disorder. These problems were the result of
477 the limitations of the original discriminant function analysis, so the superiority of EFA on these
478 data is therefore confirmed. In addition, the new factors extracted comprised only 66 items,
479 allowing SDQ-2 to be much quicker to administer than the original questionnaire.

480 The end result of this analysis is the creation of a new questionnaire, the SDQ-2, whose
481 subscales will consist of the items on the 7 factors described above. These new subscales will be
482 named: *InsPsy* (psychological features of insomnia), *InsSubj* (subjective estimate of insomnia
483 severity), *InsPLM* (insomnia due to limb movements), *EDS* (excessive daytime sleepiness), *NAR*
484 (neurological symptoms of narcolepsy), *SUBST* (sleep effects of substance use), and *SDB* (sleep-
485 disordered breathing). The fact that a similar factor structure emerged when the dataset was

486 divided into male and female respondents suggests that SDQ-2 may evaluate men and women
487 equally well, although different cut-off scores indicative of the threshold of pathology will likely
488 be needed for each gender, as on the original SDQ. On Main Factor 2, SDQ's conflation of two
489 narcolepsy symptom domains – excessive daytime sleepiness and neurological symptoms of
490 narcolepsy -- was resolved by extracting subfactors 2A and 2B. Creation of the EDS subscale
491 also resolved another problem with the original SDQ: it had confounded some of these items
492 within its PLM and PSY subscales. In effect, InsPSY replaces the original PSY subscale, while
493 InsPLM replaces the original PLM scale. The new NAR scale fully replaces the original NAR
494 scale and is now much more specific for the neurological symptoms and signs of narcolepsy,
495 while the new EDS scale independently evaluates sleepiness from whatever cause.

496 The SDB subscale contained 10 of the 12 original items from the SDQ-SA subscale.
497 While it had two subfactors, breathing difficulties and obesity, having a subscale consisting
498 entirely of weight-related questions was not thought to be useful, so these items were included in
499 Factor 4 to produce a unitary SDB subscale. Although BMI is no longer an item on SDQ-2, its
500 statistical contribution to the SDB scale is preserved by the 5-level height and weight items. For
501 those users wishing to have a numerical estimate of BMI, the look-up matrix using these two
502 items is shown in S2 Table.

503 An assessment of weight gain on the original SDQ required a clinician to perform
504 calculations using items “current weight” and “weight at age 20”. This task will be replaced on
505 SDQ-2 by a new item that asks the patient directly how much weight (if any) they have gained
506 since they were 20 years old; this new item loads on the SDB scale.

507 Of the five SDQ questions for women, only item 144 “I have gone through the
508 menopause” loaded significantly onto any of the 7 factors -- SDB. There is some evidence^[41]

509 that lower estrogen levels after menopause cause a lessening of muscle tone, which might
510 aggravate sleep apnea, so this item will be included in the SDQ-2. The other gender-related
511 questions will be discarded.

512 Being shorter than the original SDQ, the SDQ-2 is expected to have a higher completion
513 rate among patients and to be quicker to complete. As noted above, the 7 new subscales should
514 resolve the original SDQ's inadvertent over-diagnosis of narcolepsy and psychiatric features of
515 insomnia, as identified by Schwegler[8]. The new insomnia subscales also validate the work of
516 Schweer[40] and Brower[37] who proposed insomnia subscales made up of existing SDQ items.
517 In fact, 13 of the 16 items on Sweere's *Insomnia* scale appear on Main Factor 1 in the present
518 study.

519 Nevertheless, there are some cautionary notes. The sample of SDQ respondents upon
520 which the present study is based was not a random population sample. Most were either referred
521 to sleep disorder clinics with a suspected sleep disorder or were patients with another known
522 disorder that was suspected of causing sleep-wake symptoms, i.e., depression, schizophrenia,
523 alcoholism, chronic fatigue syndrome, or general medical illness. Other respondents were
524 normal university students in psychology courses or healthy control participants in clinical
525 research studies.

526 In this retrospective dataset, there were no structured interview diagnoses of respondents'
527 sleep disorders, psychiatric illnesses, or general medical conditions. Likewise, no racial / ethnic /
528 cultural information was available. Although some clinical diagnoses unrelated to sleep were
529 available, these were made by numerous clinicians in different hospitals in different years and
530 without uniform diagnostic criteria.

531 Another caution is that the data upon which the current study is based were collected over
532 a long time span, some being almost 35 years old. During this interval there were changes in
533 clinical nosology and polysomnographic measurement techniques, not to mention cultural and
534 linguistic changes. It is therefore possible that the response set of the respondents was not
535 homogeneous, introducing further error variance. On the positive side, such issues would, again,
536 be somewhat mitigated by the large sample size.

537 The present paper does not show any validation of the new subscales, although most of
538 the respondents had polysomnography. In fact, only 78 persons in this study were normal
539 controls who had no sleep complaints but even they were not age-matched to patients and did not
540 have polysomnography. Therefore, the factor structure reported here needs to be confirmed in
541 larger samples, hopefully including normal persons age-matched to polysomnographically-
542 diagnosed patients. In future validation studies, an ROC analysis of each SDQ-2 subscale will be
543 very informative and will likely find different cut-off scores in men versus women to indicate the
544 threshold for pathology.

545 Previous studies of the original SDQ-SA subscale by other authors -- using patients that
546 were not included in the present study -- have shown its accurate identification of sleep apnea.
547 Hopefully, future convergent and divergent validity studies of the new SDQ-2 subscales using
548 psychometric and physiological assessments will show even greater precision.

549 The 7 subscales proposed in the present article will allow re-analysis of SDQ datasets
550 gathered by different investigators over the years; these contain the responses of tens of
551 thousands of persons. Especially in those datasets from controlled studies of PTSD, CFS,
552 depression, and anxiety, it is possible that new insights into those patients' symptoms could be
553 obtained via these new subscales.

554 It should be noted that all of the subscales extracted by EFA in this article are based on
555 the exact wording and item-numbering of the original SDQ. It is for this reason that
556 retrospective analyses can be done on old SDQ data. However, on the new SDQ-2 questionnaire
557 there will be substantial changes in item-numbering plus a change in the form of Likert response
558 choices: from 1 . . . 5 on the original SDQ to 0 . . . 4 on the SDQ-2. There will also be re-
559 wording of several items to give greater precision in symptom description, plus a general
560 rewording to avoid adjectives about magnitude or intensity in the items' stems. For those users
561 wishing to continue using the original SDQ, it is suggested that the 4 original subscales be retired
562 in favour of the 7 new ones. For those users of the new 66-item SDQ-2, it will only be possible
563 to score it by using the 7 new scales.

564 Future goals for the SDQ-2 include studies of test-retest reliability plus validity studies
565 using other questionnaires and physiological measures. It is hoped that these will be done both in
566 the original English version and in the translated versions, which in some cases would be the first
567 validation of those translations. Such validation would facilitate comparison studies between
568 occupational, cultural, linguistic, and geographical groups.

569 A prospective study of 800 members of a large urban police force has been completed, in
570 which the 7 new SDQ-2 subscales were concurrently validated against a number of published
571 sleep and psychological questionnaires: ESS[9], ISI[42], STOP-Bang[15], Berlin
572 Questionnaire[14], GAD-7[43], PHQ-9[44], MIES[45], PCL-5[46], and CAGE[47]. A
573 manuscript on this subject is in preparation.

574 The new SDQ-2 should have more clinical utility than the original SDQ, in that it
575 identifies a greater range of sleep pathologies and does it with better precision. It may also
576 supplant various shorter single-disorder questionnaires.

577 SDQ-2 will be available for distribution from the University of Ottawa's Institute of

578 Mental Health Research at the Royal (<https://www.theroyal.ca/research/sleep-mental-health->

579 [research](#)). Technical questions can be sent by email to Dr. Douglass.

580

581

582 **Author Contributions**

583 Conceptualization: Alan Douglass, Kathleen Biard

584 Data Curation: Kathleen Biard, Alan Douglass,

585 Formal Analysis: Kathleen Biard, Alan Douglass,

586 Methodology: Alan Douglass, Kathleen Biard, Joseph De Koninck

587 Project Administration: Alan Douglass, Joseph De Koninck

588 Supervision: Alan Douglass, Joseph De Koninck

589 Writing – original draft: Alan Douglass, Kathleen Biard

590 Writing – review and editing: Alan Douglass, Kathleen Biard, Joseph De Koninck

591

592

593 **Acknowledgements**

594 Sleep Disorders Clinic, Royal Ottawa Mental Health Center (Drs. Alan Douglass, Elliott Lee,
595 and Louis Soucy) and The University of Ottawa Institute of Mental Health Research at the
596 Royal, Ottawa, Ontario, Canada

597
598 University of Michigan Psychiatry Department (Drs. John Greden, Mark Demitrack, Israel
599 Liberzon, Kirk Brower, Alan Douglass) and Neurology Sleep Disorders Clinic (Drs. Michael
600 Aldrich, Ronald Chervin), UM Medical Center, Ann Arbor, Michigan, USA

601
602 Sleep Disorders Center, Stanford University Medical Center (Drs. Christian Guilleminault,
603 William C. Dement, Sharon Keenan RPsGT), Palo Alto, California, USA.

604
605 Sleep Disorders Clinic, University of Alberta Hospital (Drs. Alan Douglass and Godfrey Man;
606 Rhoda Schreiner RPsGT), Edmonton, AB, Canada.

607
608 Psychology Dept., University of Alberta (Dr. Don Kuiken), Edmonton, AB, Canada

609
610 Harborview Medical Center, University of Washington (Dr. Dedra Buchwald), Seattle,
611 Washington, USA

612
613 Sleep Disorders Clinic, Isaac Walton Killam Hospital, Dalhousie University (Dr. Rachel
614 Moorehouse), Halifax, Nova Scotia, Canada.

615

616 **References**

- 617 1. Douglass AB, Bornstein R, Nino-Murcia G, Keenan S, Miles L, Zarcone VPJ, et al. The
618 Sleep Disorders Questionnaire. I: Creation and multivariate structure of SDQ. *Sleep*.
619 1994;17(2):160-7.
- 620
- 621 2. Miles LE. The Sleep Questionnaire and Assessment of Wakefulness. In: Guilleminault C,
622 editor. *Sleeping and waking disorders, indications and techniques*. Menlo Park, CA: Addison-
623 Wesley Pub. Co. Medical/Nursing Division: 1982. p. 383–413.
- 624
- 625 3. Douglass AB. Item test-retest reliability of the Sleep Disorders Questionnaire (SDQ).
626 *Sleep Research*. 1990;19:215.
- 627
- 628 4. Buysse DJ, Reynolds Cd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep
629 Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res*.
630 1989;28(2):193-213.
- 631
- 632 5. Guichard K, Marti-Soler H, Micoulaud-Franchi JA, Philip P, Marques-Vidal P,
633 Vollenweider P, et al. The NoSAS score: A new and simple screening tool for obstructive sleep
634 apnea syndrome in depressive disorder. *J Affect Disord*. 2018;227:136-40.
- 635
- 636 6. Valipour A, Lavie P, Lothaller H, Mikulic I, Burghuber OC. Sleep profile and symptoms
637 of sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary
638 disease. *Sleep Med*. 2011;12(4):367-72.

- 639
- 640 7. Valipour A, Lothaller H, Rauscher H, Zwick H, Burghuber OC, Lavie P. Gender-related
641 differences in symptoms of patients with suspected breathing disorders in sleep: a clinical
642 population study using the sleep disorders questionnaire. *Sleep*. 2007;30(3):312-9.
- 643
- 644 8. Schwegler K, Klaghofer R, Nirrko AC, Mathis J, Hersberger KE, Bloch KE. Sleep and
645 wakefulness disturbances in Swiss pharmacy customers. *Swiss Medical Weekly*. 2006;136(9-
646 10):149-54.
- 647
- 648 9. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness
649 Scale. *Sleep*. 1991;14(6):540-5.
- 650
- 651 10. Valencia-Flores M, Resendiz M, Castano VA, Santiago V, Campos RM, Sandino S, et al.
652 Objective and subjective sleep disturbances in patients with systemic lupus erythematosus.
653 *Arthritis And Rheumatism*. 1999;42(10):2189-93.
- 654
- 655 11. McCurry SM, Gibbons LE, Logsdon RG, Vitiello MV, Teri L. Nighttime insomnia
656 treatment and education for Alzheimer's disease: A randomized, controlled trial. *Journal of the*
657 *American Geriatrics Society*. 2005;53(5):793-802.
- 658
- 659 12. Longstreth WT, Koepsell TD, Ton TG, Hendrickson AF, Van Belle G. The epidemiology
660 of narcolepsy. *Sleep*. 2007;30(1):13-26.
- 661

- 662 13. Happe S, SchrodL B, Faltl M, Muller C, Auff E, Zeitlhofer J. Sleep disorders and
663 depression in patients with Parkinson's disease. *Acta Neurol Scand.* 2001;104(5):275-80.
664
- 665 14. Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire
666 to identify patients at risk for the sleep apnea syndrome. *Annals of Internal Medicine.*
667 1999;131:485-91.
668
- 669 15. Chung F, Yegneswaran B, Liao P, Chung SA, Vairavanathan S, Islam S, et al. STOP
670 questionnaire - A tool to screen patients for obstructive sleep apnea. *Anesthesiology.*
671 2008;108(5):812-21.
672
- 673 16. Marti-Soler H, Hirotsu C, Marques-Vidal P, Vollenweider P, Waeber G, Preisig M, et al.
674 The NoSAS score for screening of sleep-disordered breathing: a derivation and validation study.
675 *Lancet Respir Med.* 2016;4(9):742-8.
676
- 677 17. Chai-Coetzer CL, Antic NA, Rowland LS, Catcheside PG, Esterman A, Reed RL, et al. A
678 simplified model of screening questionnaire and home monitoring for obstructive sleep apnoea in
679 primary care. *Thorax.* 2011;66(3):213-9.
680
- 681 18. Schotland HM, Georeno AM, Pack AI. Obstructive sleep apnea: feasibility of a disease
682 management strategy utilizing primary care case finding. *Journal of Clinical Outcomes*
683 *Management.* 2000;7(7):34-8.
684

- 685 19. Chihorek AM, Abou-Khalil B, Malow BA. Obstructive sleep apnea is associated with
686 seizure occurrence in older adults with epilepsy. *Neurology*. 2007;69(19):1823-7.
687
- 688 20. Lancaster LH, Mason WR, Parnell JA, Rice TW, Lloyd JE, Milstone AP, et al.
689 Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. *Chest*. 2009;136(3):772-8.
690
- 691 21. Abrishami A, Khajehdehi A, Chung F. A systematic review of screening questionnaires
692 for obstructive sleep apnea. *Canadian Journal of Anaesthesia-Journal Canadien D'Anesthesie*.
693 2010;57(5):423-38.
694
- 695 22. Chervin RD. Use of clinical tools and tests in sleep medicine. In: Kryger MH, Roth T,
696 Dement WC, editors. *Principles and Practice of Sleep Medicine*, 3 ed. Philadelphia: W. B.
697 Saunders; 2000. p. 535-46.
698
- 699 23. Ramachandran SK, Josephs LA. A meta-analysis of clinical screening tests for
700 obstructive sleep apnea. *Anesthesiology*. 2009;110(4):928-39.
701
- 702 24. Seetho IW, Wilding JP. Screening for obstructive sleep apnoea in obesity and diabetes--
703 potential for future approaches. *Eur J Clin Invest*. 2013;43(6):640-55.
704
705

- 706 25. Economou NT, Dikeos D, Andrews N, Foldvary-Schaefer N. Use of the Sleep Apnea
707 Scale of the Sleep Disorders Questionnaire (SA-SDQ) in adults with epilepsy. *Epilepsy Behav.*
708 2014;31:123-6.
709
- 710 26. Klingman KJ, Jungquist CR, Perlis ML. Questionnaires that screen for multiple sleep
711 disorders. *Sleep Med Rev.* 2017;32:37-44.
712
- 713 27. Lichtblau M, Bratton D, Giroud P, Weiler T, Bloch KE, Brack T. Risk of sleepiness-
714 related accidents in Switzerland: results of an online sleep apnea risk questionnaire and
715 awareness campaigns. *Front Med (Lausanne).* 2017;4:34.
716
- 717 28. Malow BA, Bowes RJ, Lin X. Predictors of sleepiness in epilepsy patients. *Sleep.*
718 1997;20(12):1105-10.
719
- 720 29. Weatherwax KJ, Malow BA. The use of the Sleep Apnea Scale of the Sleep Disorders
721 Questionnaire in patients with epilepsy. *Sleep.* 2003;26:A223.
722
- 723 30. Bassetti C, Aldrich MS, Chervin RD, Quint D. Sleep apnea in patients with transient
724 ischemic attack and stroke: a prospective study of 59 patients. *Neurology.* 1996;47(5):1167-73.
725
- 726 31. Sacco RL. Risk factors and outcomes for ischemic stroke. *Neurology.* 1995;45(2 Suppl
727 1):S10-4.
728

- 729 32. Bronner LL, Kanter DS, Manson JE. Primary prevention of stroke. *N Engl J Med.*
730 1995;333(21):1392-400.
731
- 732 33. Bassetti C, Aldrich MS, Quint D. Sleep-disordered breathing in patients with acute supra-
733 and infratentorial strokes. A prospective study of 39 patients. *Stroke.* 1997;28(9):1765-72.
734
- 735 34. Valencia-Flores M, Orea A, Castano VA, Resendiz M, Rosales M. Prevalence of sleep
736 apnea and electrocardiographic disturbances in morbidly obese patients. *Obesity Res.*
737 2000;8(3):262-9.
738
- 739 35. Douglass AB. Validation of the "Psych" scale of the Sleep Disorders Questionnaire
740 (SDQ). *Sleep Research.* 1992;21:150.
741
- 742 36. Carroll BJ, Feinberg M, Smouse PE, Rawson SG, Greden JF. The Carroll Rating Scale
743 for Depression I: development, reliability, and validation. *British Journal of Psychiatry.*
744 1981;138(3):194-200.
745
- 746 37. Brower KJ, Aldrich MS, Hall JM. Polysomnographic and subjective sleep predictors of
747 alcoholic relapse. *Alcohol Clin Exp Res.* 1998;22(8):1864-71.
748
- 749 38. Smith S, Trinder J. Detecting insomnia: comparison of four self-report measures of sleep
750 in a young adult population. *Journal Of Sleep Research.* 2001;10(3):229-35.
751

752 39. Chesson A, Jr., Hartse K, Anderson WM, Davila D, Johnson S, Littner M, et al. Practice
753 parameters for the evaluation of chronic insomnia. An American Academy of Sleep Medicine
754 report. Standards of Practice Committee of the American Academy of Sleep Medicine. *Sleep*.
755 2000;23(2):237-41.

756

757 40. Sweere Y, Kerkhof GA, De Weerd AW, Kamphuisen HAC, Kemp B, Schimsheimer RJ.
758 The validity of the Dutch Sleep Disorders Questionnaire (SDQ). *J Psychosom Res*.
759 1998;45(6):549-55.

760

761 41. Perger E, Mattaliano P, Lombardi C. Menopause and sleep apnea. *Maturitas*.
762 2019;124:35-8.

763

764 42. Morin CM, Belleville G, Belanger L, Ivers H. The Insomnia Severity Index:
765 psychometric indicators to detect insomnia cases and evaluate treatment response. *Sleep*.
766 2011;34(5):601-8.

767

768 43. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized
769 anxiety disorder: the GAD-7. *Arch Intern Med*. 2006;166(10):1092-7.

770

771 44. Martin A, Rief W, Klaiberg A, Braehler E. Validity of the Brief Patient Health
772 Questionnaire mood scale (PHQ-9) in the general population. *Gen Hosp Psychiatry*.
773 2006;28(1):71-7.

774

- 775 45. Nash WP, Marino Carper TL, Mills MA, Au T, Goldsmith A, Litz BT. Psychometric
776 evaluation of the Moral Injury Events Scale. *Mil Med.* 2013;178(6):646-52.
777
- 778 46. Ashbaugh AR, Houle-Johnson S, Herbert C, El-Hage W, Brunet A. Psychometric
779 validation of the English and French versions of the Posttraumatic Stress Disorder Checklist for
780 DSM-5 (PCL-5). *PLoS One.* 2016;11(10):e0161645.
781
- 782 47. Nilssen O, Ries RK, Rivara FP, Gurney JG, Jurkovich GJ. The CAGE questionnaire and
783 the Short Michigan Alcohol Screening Test in trauma patients: comparison of their correlations
784 with biological alcohol markers. *J Trauma.* 1994;36(6):784-8.

Fig. 1: Scree Plot of EFA Factors (eigenvalues > 1.)




Figure 1., Scree Plot